{
    "ticker": "VSTA",
    "name": "VistaGen Therapeutics, Inc.",
    "description": "VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with central nervous system (CNS) disorders. Founded in 1998, VistaGen is pioneering the development of new treatments for anxiety, depression, and other mood disorders. The company\u2019s lead product candidate, AV-101, is being developed as a rapid-acting antidepressant that targets the NMDA receptor and is designed to provide significant relief from depressive symptoms without the side effects commonly associated with traditional antidepressants. VistaGen employs advanced stem cell technology to create proprietary drug candidates and aims to transform the treatment landscape for CNS conditions with its novel approaches. The company is committed to addressing the unmet needs of patients suffering from debilitating mental health disorders and is dedicated to advancing its clinical pipeline through rigorous research and development efforts. VistaGen's mission is to improve the lives of individuals affected by CNS disorders by delivering breakthrough therapies that offer hope and healing.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "1998",
    "website": "https://www.vistagen.com",
    "ceo": "Shawn Singh",
    "social_media": {
        "twitter": "https://twitter.com/VistaGen",
        "linkedin": "https://www.linkedin.com/company/vistagen-therapeutics/"
    },
    "investor_relations": "https://investors.vistagen.com",
    "key_executives": [
        {
            "name": "Shawn Singh",
            "position": "CEO"
        },
        {
            "name": "Jeffrey A. R. Zink",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "AV-101",
                "PH94B"
            ]
        }
    ],
    "seo": {
        "meta_title": "VistaGen Therapeutics, Inc. | Innovative Treatments for CNS Disorders",
        "meta_description": "Explore VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative therapies for CNS disorders like anxiety and depression.",
        "keywords": [
            "VistaGen",
            "Biopharmaceutical",
            "CNS Disorders",
            "Depression",
            "Anxiety",
            "AV-101"
        ]
    },
    "faq": [
        {
            "question": "What does VistaGen Therapeutics focus on?",
            "answer": "VistaGen focuses on developing innovative therapies for central nervous system disorders, including anxiety and depression."
        },
        {
            "question": "Who is the CEO of VistaGen?",
            "answer": "Shawn Singh is the CEO of VistaGen Therapeutics."
        },
        {
            "question": "Where is VistaGen headquartered?",
            "answer": "VistaGen is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are VistaGen's main product candidates?",
            "answer": "VistaGen's main product candidates include AV-101 and PH94B."
        },
        {
            "question": "When was VistaGen founded?",
            "answer": "VistaGen was founded in 1998."
        }
    ],
    "competitors": [
        "PTN",
        "AXSM",
        "SAGE",
        "MYOS"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}